Clinical trial

Attending Doctor of Shenzhen People's Hospital

Name
ShenzhenPH spine wang02
Description
Evaluation of bone mineral density and function at 1 year after screw internal fixation of osteoporotic vertebral compression fractures with desuzumab: a parallel double-blind randomized controlled clinical trial
Trial arms
Trial start
2021-09-14
Estimated PCD
2023-03-20
Trial end
2023-09-25
Status
Withdrawn
Phase
Early phase I
Treatment
Denosumab Only Product
denosumab subcutaneous injection /6 months, twice a year
Arms:
dnosumab, placebo control
Other names:
Denosumab
Primary endpoint
age
up to 12 months
sex
up to 12 months
height
up to 12 months
weight
up to 12 months
BMI
up to 12 months
osteocalcin
up to 12 months
Procollagen type 1 n-terminal propeptide P1NP
up to 12 months
C-terminal cross-linked type 1 collagen terminal peptide CTX
up to 12 months
Serum total calcium
up to 12 months
parathyroid hormone
up to 12 months
albumin
up to 12 months
lumber spine bone mineral density
up to 12 months
Hip bone mineral density
up to 12 months
MRI of lumber
up to 12 months
pain visual analogue scores (VAS)
up to 12 months
Eligibility criteria
Inclusion Criteria:• Must be age between 40 and 90 years old * X-ray diagnosis of 1-2 vertebral compression fractures * Dual energy X ray test bone mineral density T value less than -1 * fracture history lasted within 6 weeks * MRI showed bone marrow edema of injured segment * lower back pain, local spines tenderness Exclusion Criteria: * • Must be able to have no posterior vertebral wall fracture * Must be able to have no patients with intervertebral fissure * Must be able to have no infection * Must be able to have no malignancy * Must be able to have no neurological dysfunction * Must be able to have no previous use of anti-osteoporosis drugs within 6 weeks * Must be able to have no inability to perform magnetic resonance imaging * Must be able to have no prior back surgery * Must be able to have no other established contraindications for elective surgery
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-03-14

1 organization

1 product

1 indication

Product
Denosumab